Menu
Search
|

Menu

Close
X

Beigene Ltd BGNE.OQ (NASDAQ Stock Exchange Global Select Market)

124.46 USD
-12.16 (-8.90%)
As of Mar 22
chart
Previous Close 136.62
Open 135.75
Volume 104,129
3m Avg Volume 188,516
Today’s High 135.75
Today’s Low 124.25
52 Week High 220.09
52 Week Low 105.19
Shares Outstanding (mil) 59.64
Market Capitalization (mil) 8,201.16
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.58 Mean rating from 12 analysts

KEY STATS

Revenue (mm, USD)
FY18
198
FY17
238
FY16
1
EPS (USD)
FY18
-0.921
FY17
-0.183
FY16
-0.274
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
58.10
Price to Sales (TTM)
vs sector
41.37
8.84
Price to Book (MRQ)
vs sector
4.27
4.60
Price to Cash Flow (TTM)
vs sector
--
40.07
Total Debt to Equity (MRQ)
vs sector
11.41
17.66
LT Debt to Equity (MRQ)
vs sector
10.91
13.97
Return on Investment (TTM)
vs sector
-46.85
12.12
Return on Equity (TTM)
vs sector
-55.81
13.24

EXECUTIVE LEADERSHIP

John Oyler
Chairman of the Board, Chief Executive Officer, Founder, Since 2010
Salary: $97,664.00
Bonus: $1,272,070.00
Xiaobin Wu
President, Since 2018
Salary: --
Bonus: --
Howard Liang
Chief Financial Officer and Chief Strategy Officer, Since 2015
Salary: --
Bonus: --
Wendy Yan
Senior Vice President, Head of Regulatory Affairs, Since 2014
Salary: $68,510.00
Bonus: --
Jason Yang
Senior Vice President, Head of Clinical Development, Since 2014
Salary: $116,129.00
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

C/O Mourant Ozannes
Corporate Services,94 Solaris Av
Camana Bay
GRAND CAYMAN     KY1-1108

Phone: +1345.9494123
Site:

BeiGene, Ltd. is principally engaged in biopharmaceutical business. The Company is mainly engaged in the research and development, production and sales of innovative molecularly targeted and immuno-oncology drugs for the treatment of cancer. The Company's main products include Zanubrutinib (BGB-3111), Tislelizumab (BGB-A317) and Pamiparib (BGB-290).

SPONSORED STORIES